After 16 Years, the American Cancer Society Backs Routine PSA Screening — With a Risk-Tailored Timetable
Published on 11/19/2026 at 08:20 | Editorial boerse-global.deMen at average risk of prostate cancer should get a PSA test every two years between the ages of 50 and 69, provided they have first discussed the pros and cons with a clinician. That is the headline shift in a sweeping revision of American Cancer Society guidance published in CA: A Cancer Journal for Clinicians (DOI: 10.3322/caac.70112) and reported on 17 November 2026 — the organisation's first fundamental rethink of its position in 16 years.
Previously, the ACS stopped short of a general screening recommendation, advocating only that men and their doctors reach a shared decision. The new stance rests on what the society describes as markedly stronger scientific evidence: screening demonstrably lowers both deaths from prostate cancer and the number of cases caught at an advanced stage. Medical laboratories may see test volumes climb as a result.
One Framework, Four Risk Bands
Rather than a single age-based rule, the updated guideline sorts men by personal risk. Those at elevated risk are advised to begin annual checks at 45. This group covers Black men and people with a strong family history — defined as at least one first-degree relative diagnosed before age 65, or several affected first-degree relatives.
The disparity driving that advice is stark: Black men face a 67 percent higher incidence and nearly double the mortality rate compared with white men, according to the society. Non-Black men whose first-degree relative was diagnosed at 65 or older fall into a different track, testing every two years from 45 through 69.
Between 70 and 74, the guidance calls for an individual decision. Routine screening stops altogether at 75; from 75 to 79, a test is considered only for very healthy men after consulting a physician. For men 80 and older, or anyone with a life expectancy under ten years, the guideline advises against testing.
Age-specific reference ranges accompany the recommendations: 1.4 to 2.5 ng/ml for men under 40; up to 2.0 to 2.5 ng/ml from 40 to 49; up to 3.1 to 3.5 ng/ml from 50 to 59; up to 4.1 to 4.5 ng/ml from 60 to 69; and up to 4.4 to 6.5 ng/ml from 70 onward.
From Threshold to Biopsy: The Diagnostic Ladder
When a reading reaches at least 3.0 ng/ml in men aged 45 to 69, or at least 6.5 ng/ml in those aged 70 to 74, the ACS protocol calls for a repeat measurement within two weeks to three months. If the elevation is confirmed, magnetic resonance imaging (MRI) or validated biomarkers should be used before any tissue sample is taken. Should a low-risk tumour then be confirmed, active surveillance is the preferred option.
The policy aligns with recent research. A European long-term study published in the New England Journal of Medicine in 2025, which followed 162,000 men aged 55 to 69 for 23 years, found 13 percent fewer prostate cancer deaths in the group invited for screening — an absolute reduction of roughly two deaths per 1,000 men.
How Germany Handles It
For comparison, German guidelines offer testing from age 45 to anyone who requests early detection, with the cost — typically €25 to €50 — usually paid out of pocket. There, a reading below 1.5 ng/ml triggers a follow-up after five years; between 1.5 and 2.99 ng/ml, no later than two years; and from 3.0 ng/ml, a repeat within three months.
Urologists caution that PSA levels can also rise because of inflammation, benign prostate enlargement, cycling or sexual intercourse — which is why the overall clinical picture for each patient remains the deciding factor.
